FARALLON CAPITAL MANAGEMENT, L.L.C.FARALLON CAPITAL MANAGEMENT, L.L.C.

Institutional investor · Portfolio as of Q3 2023

SEC EDGAR SourceSEC Filings

Top Holdings164 positions

Checking export access…
Activity:
Stock
Shares
Value
Weight
Avg Buy
Est. P&L
Held
Conviction
SPYSPY
PUT

STATE STREET SPDR S&P 500 ETF TRUST CL USD INC

8.7M$3.7B17.4%
Increased

ACTIVISION BLIZZARD INC

20.3M$1.9B8.9%
7 qtrssince 2022-Q1
Increased
100
VMWVMWDelisted

VMWARE INC

5.5M$915.4M4.3%
6 qtrssince 2022-Q2
Increased
80

HORIZON THERAPEUTICS PLC

6.7M$770.1M3.6%
10 qtrssince 2021-Q2
Decreased
0

UNITEDHEALTH GROUP INC

1.3M$679M3.2%$451.25+7.00%
3 qtrssince 2023-Q1
Increased
62

TRANSUNION

9.2M$662.9M3.1%$86.03-17.55%
20 qtrssince 2018-Q4
Decreased
0

EXELIXIS INC

25.9M$565M2.6%$18.94+15.34%
20 qtrssince 2018-Q4
Unchanged
0

IQVIA HOLDINGS INC

2.8M$544.3M2.5%$159.39+23.44%
20 qtrssince 2018-Q4
Decreased
0

THERMO FISHER SCIENTIFIC INC

1M$530.2M2.5%$418.23+20.19%
16 qtrssince 2019-Q4
Decreased
0

SALESFORCE.COM INC

2.5M$512.1M2.4%$173.51+15.47%
16 qtrssince 2019-Q4
Increased
68

CHARTER COMMUNICATIONS INC - CLASS A

1.1M$488.8M2.3%$439.820.00%
1 qtr
New
81
SGENSGENDelisted

SEAGEN INC

2.3M$481.7M2.2%
3 qtrssince 2023-Q1
Increased
87

ALPHABET INC-CL C

3.6M$469M2.2%$98.46+32.91%
20 qtrssince 2018-Q4
Decreased
0

MICROSOFT CORP

1.3M$426M2.0%$214.60+44.68%
20 qtrssince 2018-Q4
Increased
70

ARAMARK

12.1M$421.1M2.0%$24.75-1.90%
12 qtrssince 2020-Q4
Increased
55
AZNAZN
ADR

ASTRAZENECA PLC

6.1M$410.4M1.9%$115.41+12.04%
9 qtrssince 2021-Q3
Unchanged
0

S&P GLOBAL INC

999,395$365.2M1.7%$318.41+12.79%
6 qtrssince 2022-Q2
Decreased
0

WABTEC CORP

3.3M$346M1.6%$72.97+43.97%
20 qtrssince 2018-Q4
Increased
49

ANALOG DEVICES INC

1.9M$340M1.6%$181.57-7.15%
2 qtrssince 2023-Q2
Decreased
0

CBRE GROUP INC - A

4.5M$333.9M1.6%$73.860.00%
1 qtr
New
71
$21.4B
AUM
164
Positions
Q3 2023
Filing
Rating · 1.5
Quarterly Portfolio Change
-11%Q2'22$18.4B-1%Q3'22$18.2B-7%Q4'22$16.9B+8%Q1'23$18.3B+9%Q2'23$19.9B+8%Q3'23$21.4B
Activity profile
$ moved · Q3'23
New17%Increased44%Decreased21%Exited18%
Composition
Equity vs derivatives
Equity83%Puts17%Calls0%
Holding period
Avg 2.1 years
<1Q15%1-4Q13%1-2Y24%2Y+48%

FARALLON CAPITAL MANAGEMENT, L.L.C. manages $21.4B across 164 positions as of Q3 2023. Top holdings: SPY (17.4%), ATVI (8.9%), VMW (4.3%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 1.5/5.0.

Q3 2023 Summary

Active quarter - 33 new positions, 41 exits, 27 increased. Top move: ATVI (INCREASED, conviction 100). Portfolio: $21.4B across 164 positions.

Top holdings by portfolio weight

Total AUM$18B
ATVI8.88%
VMW4.27%
HZNP3.59%
UNH3.17%
TRU3.09%
EXEL2.64%
IQV2.54%
TMO2.47%
CRM2.39%
CHTR2.28%
Other2.25%

Portfolio allocation by GICS sector

Sectors11
Healthcare30.94%
Unknown25.38%
Technology13.15%
Financial Services11.17%
Communication Services7.48%
Industrials5.74%
Real Estate3.62%
Basic Materials1.60%
Consumer Cyclical0.44%
Utilities0.40%
Other0.08%

Behavioral investing profile

Checking access…
Balanced Allocator- primarily Healthcare, Unknown, Technology
Compare DNA across all funds
7-dimension quality assessment
Below Average(1.5 / 5.0)
Track Record60
Conviction43
Concentration66
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
8Q
CRNXCRNXCRINETICS PHARMACEUTICALS IN
Q3 2024 Q2 2026+8.5M shares+$314.1M
7Q
BBIOBBIOBRIDGEBIO PHARMA INC
Q4 2024 Q2 2026+9M shares+$755.7M
5Q
BSXBSXBOSTON SCIENTIFIC CORP
Q2 2025 Q2 2026+6.8M shares+$69.5M
Checking access…

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used